EPAM vs LCTX · P/E 14, rev $2.81B vs rev $2.8M
EPAM Systems Inc (EPAM) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
EPAM Systems Inc (EPAM) is a information technology services company listed on US.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Latest reported EPAM revenue for 2026-06-30 was $2.81B. Net income was $185.5M. EPAM currently screens at market cap $5.10B and trailing P/E 14.0.
Latest reported LCTX revenue for 2026-06-30 was $2.8M. Net income was -$3.3M. Revenue was up 62.0% from 2026-03-31 to 2026-06-30. LCTX currently screens at market cap $213.6M.
EPAM currently screens at market cap $5.10B and trailing P/E 14.0. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the EPAM and LCTX stock pages for the full models.
Not investment advice.